PatternsRadar
Sign in

BALPHARMABal Pharma Limited

NSE
Full chart
101.46INR-5.33 (-4.99%)Close · 6 Oct 2026
12 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹162 CrMarket cap
22.3P/E (TTM)
100.0%Delivery

Filings & corporate actions

89 results filed
CSV
Next results · Q2 FY27
Expected 9 Nov 2026 – 15 Nov 2026
Estimate: filed 40–46 days after quarter end, last 5 times
Dividend
₹1.20 per share · last 17 Sept 2026
2026
  • 17 SeptdividendDividend · ₹1.20 per share+1.1%
  • 12 AugresultsResults · Q1 FY27 · consolidated and standalone-2.5%NSE
  • 13 JulshareholdingShareholding · 30 Jun 2026-0.3%NSE
  • 27 MayresultsResults · Q4 FY26 · consolidated and standalone-6.5%NSE
  • 8 AprshareholdingShareholding · 31 Mar 2026+5.7%NSE
  • 11 FebresultsResults · Q3 FY26 · consolidated and standalone+4.7%NSE
  • 13 JanshareholdingShareholding · 31 Dec 2025-1.2%NSE

Reaction to results · all yearsrose on day 0 in 26 of 79 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2712 Aug 2026-2.5%-4.2%+17.4%0.6×
Q4 FY2627 May 2026-6.5%-10.6%-17.7%1.7×
Q3 FY2611 Feb 2026+4.7%+8.7%-3.5%2.6×
Q2 FY2612 Nov 2025-2.1%-4.7%-10.6%1.8×
Q1 FY2611 Aug 2025-2.1%-6.0%-4.5%1.3×
Q4 FY2529 May 2025-2.5%+0.7%+0.2%2.2×
Q3 FY2514 Feb 2025-4.5%-4.0%-18.1%3.2×
Q2 FY2515 Nov 2024+5.0%+9.3%+2.0%5.3×
Q1 FY2513 Aug 2024-9.0%-4.0%+9.2%4.8×
Q4 FY2429 May 2024+0.7%-6.8%-2.3%21.8×
Q3 FY2413 Feb 2024-5.3%+0.7%-15.4%0.5×
Q2 FY249 Nov 2023+0.9%+21.4%+13.6%1.4×
Q1 FY2411 Aug 2023-1.1%-0.8%-0.8%0.4×
Q4 FY2330 May 2023-0.4%+7.5%+12.5%0.5×
Q3 FY237 Feb 2023+0.4%-6.6%-9.4%0.7×
Q2 FY2315 Nov 2022-1.4%-4.8%-3.7%0.9×
Q1 FY2312 Aug 2022-2.3%-3.7%+2.2%0.5×
Q4 FY2231 May 2022-0.7%-0.2%-1.3%1.2×
Q3 FY2211 Feb 2022-4.3%-9.9%-8.4%0.3×
Q2 FY2211 Nov 2021-1.9%-5.6%+2.6%1.2×
Q1 FY2211 Aug 2021+1.9%+2.4%+6.4%1.6×
Q4 FY2130 Jun 2021-1.7%-5.6%-7.5%1.1×
Q3 FY2112 Feb 2021-3.5%-9.5%+2.5%3.5×
Q2 FY2112 Nov 2020-2.0%-4.8%+1.5%0.2×
Q1 FY219 Sept 2020+0.8%+5.7%+24.3%1.2×
Q4 FY2030 Jul 2020+4.4%+5.8%+12.5%3.4×
Q3 FY2012 Feb 2020-4.2%-13.4%-36.6%0.6×
Q2 FY2015 Nov 2019-4.0%-10.4%-11.9%0.5×
Q1 FY2014 Aug 2019-6.5%-26.9%-4.0%0.6×
Q4 FY1926 Jun 2019+0.5%+3.1%-14.9%1.8×
Q3 FY1926 Feb 2019-3.6%-0.6%-4.9%4.0×
Q2 FY1926 Nov 2018-0.9%-0.2%-0.6%0.3×
Q1 FY1923 Aug 2018-2.3%-1.5%-0.1%1.2×
Q4 FY186 Jul 2018-0.2%-0.3%+1.4%0.2×
Q3 FY1813 Mar 20180.0%-5.1%-6.1%0.5×
Q2 FY1813 Dec 2017-2.1%-2.2%+16.9%0.7×
Q1 FY1822 Sept 2017-3.6%-3.1%-2.4%0.8×
Q4 FY1715 Jun 2017+2.1%+16.5%+8.6%0.7×
Q3 FY179 Feb 2017-0.6%-4.3%-4.5%0.8×
Q2 FY1718 Nov 2016-0.3%-1.2%+1.1%0.8×
Q1 FY1712 Aug 2016-1.7%-1.1%+6.6%0.2×
Q4 FY1629 May 2016+2.2%-0.3%-0.2%1.6×
Q3 FY1613 Feb 2016+1.1%-2.4%+24.6%1.2×
Q2 FY1610 Nov 2015+3.4%-2.9%+53.1%0.3×
Q1 FY1614 Aug 2015-2.0%-9.4%+0.6%0.6×
Q4 FY1529 May 2015-4.3%-18.6%-18.3%1.5×
Q3 FY1519 Feb 2015+0.3%-4.7%+1.1%0.6×
Q2 FY1513 Nov 2014-1.3%-7.6%-9.0%0.2×
Q1 FY1518 Aug 2014-0.9%-2.6%+6.7%0.3×
Q4 FY143 Jul 2014+5.0%+4.4%+17.4%0.3×
Q3 FY1418 Feb 2014+4.9%+28.9%+24.1%3.3×
Q2 FY1421 Nov 20130.0%+2.3%+9.1%0.6×
Q1 FY1414 Aug 2013+1.3%+8.8%0.0%1.2×
Q4 FY1327 Jun 2013+18.7%+18.7%+21.4%0.9×
Q3 FY1320 Feb 2013-1.2%-1.2%-5.9%0.3×
Q2 FY1312 Nov 2012-0.2%+5.7%+17.8%0.4×
Q1 FY1321 Aug 2012-1.3%-3.1%+17.3%0.4×
Q4 FY1211 May 2012-2.0%-5.3%-7.3%0.6×
Q3 FY126 Feb 2012-5.0%-5.2%-14.4%1.6×
Q2 FY128 Nov 2011+1.4%-16.7%-14.0%2.4×
Q1 FY1223 Aug 2011-0.9%+0.2%-0.2%1.0×
Q4 FY1113 May 2011+10.1%+12.1%+13.3%6.2×
Q3 FY1131 Jan 2011-1.8%-4.2%-8.1%0.0×
Q2 FY1113 Nov 2010-3.6%-15.8%-22.0%0.3×
Q1 FY119 Aug 2010-0.7%-5.4%-2.5%0.2×
Q4 FY1014 May 2010-2.0%-0.7%-4.1%0.4×
Q3 FY1027 Jan 2010+0.2%-5.4%-7.4%0.5×
Q2 FY1031 Oct 2009-3.9%+4.1%+7.1%0.9×
Q1 FY1027 Jul 2009+2.1%+0.7%+14.3%1.3×
Q4 FY0929 Jun 2009+2.4%-7.4%-6.6%0.7×
Q3 FY0931 Jan 2009-1.0%+1.9%-12.5%0.0×
Q2 FY0927 Oct 2008+18.2%+14.2%+0.3%0.0×
Q1 FY0930 Jul 2008-2.1%+7.5%+4.3%1.1×
Q4 FY0824 Jun 2008-6.3%-14.6%-12.8%1.0×
Q3 FY0824 Jan 2008-1.8%-1.8%-2.8%0.2×
Q2 FY0831 Oct 2007-0.7%+3.3%+20.1%3.7×
Q1 FY0830 Jul 2007+2.3%+5.2%+0.6%0.4×
Q4 FY071 Jul 2007+0.2%-4.6%-11.5%1.0×
Q3 FY073 Feb 2007-2.8%-8.1%-22.4%0.1×
Average-0.4%-1.4%+0.3%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+34.5%
Profit YoY+445.7%
Interest cost YoY+3.4%
Revenue QoQ+5.4%
Profit QoQ-68.4%
CAGR2Y3Y4Y5Y6Y7Y
Revenue-1.3%+3.1%+4.5%—+11.5%—
Profit-2.4%+44.0%+13.7%———

Key data

CSV
Open103.01
Day range101.46 – 105.00
52-week range60.00 – 124.60
From 52w high-18.6%
RSI (14)50.0
ATR (14)6.41
Volume21.9K
Avg volume (20D)1.58L
Rel volume0.14×
Volatility (1Y)45.2%
Turnover₹22.2L
SMA 50 / 20094.33 / 81.15

Delivery percentage

Latest · 6 Oct 2026100.0%
20-day avg50.8%
1-year avg63.8%
Percentile (own history)100th
Range8.6–100.0%
Sessions1,731

Over the last 20 sessions BALPHARMA settled 50.8% of its traded quantity, which is above average for an NSE equity. Its one-year average is 63.8%, so recent sessions are running 12.9 points lower than usual. That is the highest reading in the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price-4.99%-3.16%+15.68%+28.15%+55.14%+22.40%

Valuation

CSV
Market cap₹162 Cr
P/E (TTM)22.3
EPS (TTM)4.55
Shares outstanding1.59Cr
Listed8 May 2006

Ownership

CSV
Promoter50.86%
Promoter Δ QoQ0.00 pp
Public49.14%
FII0.15%
DII0.00%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)74.087.784.188.6
YoY chg+0.4%+19.9%+2.7%+34.5%
Net profit (₹ Cr)0.71.83.61.1
YoY chg-31.1%+245.7%-33.0%+445.7%
Net margin1.0%2.0%4.3%1.3%
EPS0.451.122.260.71

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 50.86% · public 49.14%
30 Sept 2021: promoter 46.87%31 Dec 2021: promoter 49.57%31 Mar 2022: promoter 49.57%13 Apr 2022: promoter 52.00%30 Jun 2022: promoter 52.00%30 Sept 2022: promoter 52.00%31 Dec 2022: promoter 51.61%31 Mar 2023: promoter 51.61%30 Jun 2023: promoter 51.61%30 Sept 2023: promoter 51.61%31 Dec 2023: promoter 51.23%31 Mar 2024: promoter 51.23%30 Jun 2024: promoter 51.23%30 Sept 2024: promoter 50.86%31 Dec 2024: promoter 50.86%31 Mar 2025: promoter 50.86%30 Jun 2025: promoter 50.86%30 Sept 2025: promoter 50.86%31 Dec 2025: promoter 50.86%31 Mar 2026: promoter 50.86%30 Jun 2026: promoter 50.86%
2021-092026-06
  • Promoter
  • Public and others
Promoter
50.86%
Public
49.14%
Promoter change
0.00 pp
Filed
13 Jul 2026
FII
0.15%
DII
0.00%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations92.581.794.674.473.773.281.965.974.087.784.188.6
Other income0.10.12.50.8(0.2)0.51.10.71.10.3(0.2)0.4
Total income92.781.897.175.273.573.783.066.675.188.083.889.1
Total expenses91.180.591.374.672.173.180.466.474.486.280.687.9
└ Finance costs3.83.74.14.23.75.03.94.13.94.94.14.5
└ Depreciation2.43.02.22.42.52.72.22.52.33.23.12.8
Profit before tax1.61.35.80.61.40.62.60.20.71.83.21.1
Tax expense0.60.40.20.40.30.0(2.8)0.00.00.0(0.4)0.0
Net profit1.00.85.50.31.00.55.40.20.71.83.61.1
EPS0.620.543.730.160.650.333.400.130.451.122.260.71
Net margin1.05%1.04%5.85%0.35%1.41%0.71%6.57%0.32%0.97%2.04%4.29%1.28%
PBT margin1.73%1.55%6.08%0.83%1.85%0.77%3.17%0.32%0.97%2.04%3.83%1.28%
Tax rate39.39%32.93%3.81%57.98%23.47%8.55%-108.93%0.00%0.00%0.00%-12.01%0.00%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 12 Aug 2026.

BALPHARMA at a glance

  • BALPHARMA closed at ₹101.46 on 6 Oct 2026, -4.99% on the day, +22.4% over one year, 18.6% below its 52-week high of ₹124.6.
  • Delivery was 100.0% of traded quantity on 6 Oct 2026, the 100th percentile of its own 1,731 sessions with a reading (20-session average 50.8%, 1-year average 63.8%).
  • Market capitalisation is ₹162 crore at a trailing P/E of 22.3 (trailing EPS ₹4.55).
  • Q1 FY27 results (consolidated, filed 12 Aug 2026): revenue ₹89 crore (+34.5% year on year), net profit ₹1 crore (+445.7%); the price moved -2.5% on the first session after.
  • Promoters held 50.86% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 9 Nov 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE083D01012
SeriesBE
Listed8 May 2006
History from8 May 2006
Sessions4,977

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE